Biogen’s Spinraza to go before NICE
January 22, 2018Sales and Marketing Biogen, Spinraza, biotech, drugs, pharma, pharmaceutical
Biogen received marketing approval from the European Commission for Spinraza (nusinersen), its treatment for spinal muscular atrophy (SMA), in May …
Abcam acquires rights to over 700 Roche products in new licensing deal
January 22, 2018Sales and Marketing Abcam, Roche, partnership, pharma
Roche has entered a licensing agreement Abcam which gives the British biotech exclusive access to the marketing rights for 760 …
Court fines Dr Reddy’s for improperly packaging products
January 22, 2018Sales and Marketing Dr Reddy's, biotech, drugs, pharma, pharmaceutical
On 18 December 2017, the District of New Jersey filed a complaint against Dr. Reddy’s Laboratories for failing to comply …
20,000 left disabled in UK due to sodium valproate use during pregnancy
January 22, 2018Medical Communications, Sales and Marketing Epilim, Sanofi, Sodium valproate, UK, pharma
Liberal Democrat MP Norman Lamb has drawn attention to what he has called an “extraordinary scandal” in which an estimated …
Sanofi finally seals big deal with $11.6bn for Bioverativ
January 22, 2018Sales and Marketing Sanofi, biotech, bioverativ, drugs, pharma, pharmaceutical
Sanofi interest in making a big acquisition has been clear for the last few years and its struggles to solidify …
AstraZeneca scores double approvals in Japan for asthma and ovarian cancer
January 19, 2018Medical Communications, Sales and Marketing AstraZeneca, Cancer, Fasenra, Japan, asthma, lynparza, ovarian cancer, pharma
AstraZeneca has unveiled a double dose of approvals awarded to its medicines in Japan: Fasenra (benralizumab) has been given authorisation …
Top Ten most popular articles on Pharmafile.com this week
January 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Boehringer, CAR T, CAR-T, Celgene, Kymriah, Merck KGaA, Novartis, Philippines, Sanofi, gilotrif, juno therapeutics, nestle, top ten
It’s Friday, so it’s time to bring you another run-down of the top ten most popular articles with Pharmafile.com’s readers …
Novartis enters biosimilar agreement with Biocon
January 19, 2018Medical Communications, Sales and Marketing Biocon, Novartis, Sandoz, biosimilars, biotech, drugs, pharma, pharmaceutical
Novartis’ Sandoz unit had already staked a claim to being one of the leaders in the developing biosimilar market and …
Pfizer’s Xalkori sees rejection at the hands of NICE in lung cancer
January 19, 2018Medical Communications, Sales and Marketing Cancer, NCIE, NSCLC, Pfizer, UK, Xalkori, lung cancer, pharma
UK regulator NICE has announced its decision not to recommend Pfizer’s Xalkori (crizotinib) for use on the NHS in the …
Gilead aims to claim edge with Pfizer CAR-T combo
January 18, 2018Medical Communications, Research and Development Gilead, Kite, Yescarta, biotech, drugs, pharma, pharmaceutical
Although those in pharma often dislike any references to drugs competing with each other for market as in a ‘race’, …
AstraZeneca expands drug discovery collaboration with X-Chem
January 18, 2018Research and Development, Sales and Marketing AstraZeneca, X-Chem, pharma
AstraZeneca and X-Chem are to expand their existing drug discovery collaboration, it has emerged. The partnership marks the third agreement …
Riding the wave: The FDA and real world evidence
January 18, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, pharma, pharmaceutical, real world evidence
Following on from this week’s earlier piece on real world evidence, Jacqueline Corrigan-Curay, Director of CDER’s Office of Medical Policy at the FDA, …
NICE meets Janssen halfway over Darzalex
January 18, 2018Medical Communications, Sales and Marketing J&J, JJ, Janssen, biotech, darzalex, drugs, pharma, pharmaceutical
NICE rejected Janssen’s Darzalex (Daratumumab) back in March last year, concluding that it wasn’t able to accurately determine the efficacy …
Evidence mounts yet again against efficacy of common morning sickness pill
January 18, 2018Research and Development Diclegis, morning sickness, pharma
Evidence is mounting against the efficacy of the common morning sickness pill pyridoxine-doxylamine (Diclegis, Diclectin), as new study data reveals …
Research calls for BRCA testing in all women
January 18, 2018Medical Communications, Research and Development BRCA, biotech, drugs, pharma, pharmaceutical
For women, possessing a mutated BRCA1 or BRCA2 gene significantly increases the chances of developing breast or ovarian cancer; at …
Ipsen ends P3 trial on liver cancer early due to strong data
January 18, 2018Research and Development Cabometyx, Exelixis, biotech, drugs, ipsen, pharma, pharmaceutical
Ipsen and Exelixis, partners in developing Cabometyx (cabozantinib), have revealed that they have cut short a Phase 3 trial into …
Novartis’ CAR T therapy Kymriah scores accelerated approval in both Europe and US
January 17, 2018Research and Development, Sales and Marketing CAR T, CAR-T, EMA, Europe, FDA, Kymriah, Novartis, US, pharma
Following up last year’s ground-breaking news that CAR T therapy Kymriah had become the first such treatment to be approved …
Fully biodegradable sensor offers safer way to monitor lung and brain conditions
January 17, 2018Research and Development biodegradable sensor, pharma, university of connecticut
Engineers at the University of Connecticut have developed a biodegradable pressure sensor which is designed to, once ingested, aid in …
Celgene rumoured to be revving up for Juno buyout
January 17, 2018Research and Development, Sales and Marketing CAR-T, Celgene, Juno, biotech, drugs, pharma, pharmaceutical
Celgene has already started off the year with a bang, announcing a deal with Impact Biomedicines worth a potential $7 …
Digital solutions from Veeva’s European Commercial & Medical Summit
January 17, 2018Medical Communications, Research and Development biotech, drugs, pharma, pharmaceutical, veeva
When Peter Gassner, CEO and founder of Veeva, provided the keynote speech at the company’s European Commercial & Medical Summit, …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
